ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olaparib

Also written as “Olaparib”, “AZD2281” and “KU-0059436 (AZD2281)(PARP inhibitor)”.

Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Prostatic Neoplasms · Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 6 companies.

Drug pageOlaparib: every studyMany companies study it; this page follows only the 76 they lead. All 323 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 10, 201576 company-led studies, 22 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only5915 open or runningphase 4since Jun 10, 2015Jun 27, 2007Apr 6, 2027phase 3 · NCT04421963
Merck125 open or runningphase 3since Mar 29, 2018Aug 3, 2016May 5, 2027phase 3 · NCT04380636
Novartisits history only20 open or runningphase 3since Jan 25, 2021Jan 25, 2021none ahead
Boryung Pharmaceuticalits history only11 open or runningphase 1since Jul 7, 2025Jul 7, 2025none ahead
CSPC Pharmaceutical Groupits history only10 open or runningphase 1since Apr 7, 2024Apr 7, 2024none ahead
Daewoong Pharmaceuticalits history only11 open or runningphase 1since Jan 19, 2026Jan 19, 2026Mar 2027phase 1 · NCT07371104

Also a collaborator on its studies: Myriad Genetic Laboratories, Frontier Science & Technology Research Foundation, Hoffmann-La Roche, Myriad Genetics, Iqvia Pty, Covance, Theradex, Parexel and KuDOS Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2016First study: phase 2 study in Metastatic Castration-Resistant Prostate CancerFirst studyNCT02861573 · 1,200 enrolled
  2. Mar 29, 2018Phase 3 study in Hematologic NeoplasmsNCT03486873 · 3,500 planned · United States, Argentina, Australia and more
  3. Nov 12, 2018Phase 3 study in Ovarian NeoplasmsNCT03740165 · 1,367 enrolled · United States, Australia, Belgium and more
  4. Nov 14, 2018Phase 2 study in Advanced Solid NeoplasmsNCT03742895 · 329 enrolled · United States, Argentina, Australia and more
  5. Feb 6, 2019Phase 3 study in Prostatic NeoplasmsNCT03834519 · 793 enrolled · United States, Argentina, Australia and more
  6. Jun 3, 20192 phase 3 studies in CarcinomaNCT03976362, NCT03976323
  7. Oct 9, 2019Phase 2 study in Solid TumorsNCT04123366 · 333 enrolled · United States, Argentina, Australia and more
  8. Dec 5, 2019Phase 2 study in Triple Negative Breast NeoplasmsNCT04191135 · 462 enrolled · United States, Canada, Chile and more
  9. May 5, 2020Phase 3 study in Lung NeoplasmsNCT04380636 · 870 enrolled · United States, Argentina, Canada and more
  10. Jul 1, 2020Phase 3 study in Colorectal NeoplasmsNCT04456699 · 335 enrolled · United States, Australia, Belgium and more
  11. Nov 5, 2020Phase 3 study in Small Cell Lung CarcinomaNCT04624204 · 672 enrolled · United States, Australia, Belgium and more

Ahead

  1. May 5, 2027Primary completion: phase 3 study in Lung NeoplasmsNCT04380636
  2. Oct 22, 2027Primary completion: phase 2 study in Metastatic Castration-Resistant Prostate CancerNCT02861573
  3. Oct 28, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT04624204
  4. Aug 4, 2043Primary completion: phase 3 study in Hematologic NeoplasmsNCT03486873

TargetBeta

“PARP 1, 2 and 3 inhibitor”ChEMBL 37, by rule

Studies

All 12 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04624204Small Cell Lung Carcinoma · United States, Australia, Belgium and more3Active, not recruitingOct 28, 2027672
NCT04456699Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedMar 27, 2023335
NCT04380636Lung Neoplasms · United States, Argentina, Canada and more3Active, not recruitingMay 5, 2027870
NCT04191135Triple Negative Breast Neoplasms · United States, Canada, Chile and more2TerminatedDec 15, 2022462
NCT04123366Solid Tumors · United States, Argentina, Australia and more2CompletedJun 8, 2026333
NCT03976362Carcinoma · United States, Argentina, Australia and more3CompletedSep 21, 2023851
NCT03976323Carcinoma · United States, Argentina, Australia and more3CompletedFeb 7, 20241,003
NCT03834519Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedMar 14, 2022793
NCT03742895Advanced Solid Neoplasms · United States, Argentina, Australia and more2Active, not recruitingAug 12, 2025329
NCT03740165Ovarian Neoplasms · United States, Australia, Belgium and more3CompletedAug 26, 20241,367
NCT03486873Hematologic Neoplasms · United States, Argentina, Australia and more3RecruitingAug 4, 20433,500
NCT02861573Metastatic Castration-Resistant Prostate Cancer2Active, not recruitingOct 22, 20271,200

How it is read

Names in the registry

  • “Olaparib”, 38 entries
  • “olaparib”, 10 entries
  • “AZD2281”, 10 entries
  • “KU-0059436 (AZD2281)(PARP inhibitor)”, 10 entries
  • “Olaparib 300mg tablets”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.